[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359117-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359117-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-conjugation-of-antibodies-to-heat-shock-protein-70-activates-immune-responses-against-tumor-cells","The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells","","Targets and Therapy presents an original research study investigating how commercial antibodies conjugated with Mycobacterium-derived HSP70 can enhance host immune responses against cancer cells. Recombinant HSP70 was combined with trastuzumab and bevacizumab for in vitro and in vivo evaluation across multiple tumor cell lines, complemented by complement fixation assays and histopathology. Results showed stronger cytotoxicity, classical complement activation, and reduced xenograft tumor growth and weight, with decreased PECAM-1 and an overall safety profile.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-conjugation-of-antibodies-to-heat-shock-protein-70-activates-immune-responses-against-tumor-cells/359117/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-conjugation-of-antibodies-to-heat-shock-protein-70-activates-immune-responses-against-tumor-cells/359117.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were antibodies conjugated with HSP70 used in the study?","Question",{"text":63,"@type":64},"Recombinant HSP70 was conjugated with monoclonal antibodies trastuzumab and bevacizumab. The resulting complexes were applied to tumor cells in vitro and in vivo in mouse xenograft models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which tumor cell lines and mechanisms were assessed?",{"text":68,"@type":64},"The cytotoxicity of the antibody-HSP70 complex was tested on MCF-7, LS174T, and HEK293T cells. Target expression was characterized, and complement activation pathways were examined using a complement fixation assay.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding immune activation and tumor outcomes?",{"text":72,"@type":64},"The complex produced significantly greater cytotoxicity than other treatments on MCF-7 and LS174T cells and activated the classical complement pathway. In xenograft tumors, treatment reduced tumor weight and growth rate, decreased PECAM-1 expression, and showed safety in histopathology.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359117,1790591393,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","ImmunoTargets and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nThe Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells  \nMohammad Khosravi , Arezoo Rajaei, Babak Mohammadian, Masoudreza Seyfi Abad Shapouri Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Khuzestan, Iran  \nCorrespondence: Mohammad Khosravi, Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Khuzestan, Iran, Tel +989163803916, [Email m.khosravi@scu.ac.ir](Email m.khosravi@scu.ac.ir)  \n\n| Purpose: The heat shock proteins (HSPs) of Mycobacterium have been identified as immunogenic antigens with chaperone functions. This study evaluated a method to enhance host immune responses against cancer cells by utilizing commercial antibodies conjugated with HSP70 derived from Mycobacterium avium subsp. paratuberculosis.\u003Cbr>Methods: Recombinant HSP70, in conjugation with the monoclonal antibodies trastuzumab and bevacizumab, was employed for both in vivo and in vitro treatment of tumor cells. The cytotoxicity of the antibody-HSP70 complex was assessed on the MCF-7, LS174T, and HEK293T cell lines, after characterization of the cells for expression of the targets. The stimulation of complement activation pathways was examined using a complement fixation assay. The in vivo effects of the HSP70- antibodies were evaluated against xenograft LS174T and MCF-7 tumors in mice. The tumor tissues were evaluated through histopathological analysis.\u003Cbr>Results: The cytotoxic effect of the antibody-HSP70 complex was significantly greater than that of other treatments against the MCF- 7 and LS174T cell lines; this effect was confirmed in the presence of human plasma and leukocyte samples. Additionally, activation of the classical complement pathway has been demonstrated using HSP70 antibodies. Treatment of xenograft tumors with the antibodyHSP70 complex significantly reduced both tumor weight and growth rate, as well as decreased the expression of platelet endothelial cell adhesion molecule-1 (PECAM-1). Histopathological analysis, along with the observed therapeutic efficacy, confirmed the safety of this approach.\u003Cbr>Conclusion: Overall, stimulating the immune system against cancer cells by targeting innate immune responses could enhance the effectiveness of targeted therapies.\u003Cbr>Keywords: heat shock protein 70, Mycobacterium avium subspecies paratuberculosis, cancer, antibody |\n| --- |\n| Introduction\u003Cbr>In recent decades, targeted therapies have been developed for cancer immunotherapy; however, their effectiveness, specificity, and accessibility remain limited. The targeted therapy approach faces challenges due to the presence of nonspecific antigens on cancer cells. Antibodies have been employed to target tumor growth factors, ligands, and angiogenesis factors.1 Monoclonal antibodies used in cancer treatment induce tumor cell cytotoxicity through various mechanisms. This collaboration between antibodies and the immune system is facilitated by processes such as antibody-dependent cellmediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) . Additionally, these antibodies can be used to deliver functional molecules, such as drugs and toxins, thereby enhancing cytotoxic effects.2\u003Cbr>Trastuzumab, marketed under the trade name Herceptin, is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2) protein. This receptor could be found in various tissues, including breast and stomach tissue. HER2 stimulates the epidermal growth factor, promoting the growth and division of cancer cells. Additionally, it activates two primary signaling pathways that simultaneously sustain cell division and inhibit mechanisms of cell death.3 Bevacizumab, known by the trade names Avastin and Stivant, is a recombinant monoclonal antibody |\n\n[https://doi.org/10.2147/ITT.S565942](https://doi.","cbCaicqKPqSXfIgo","https://ap.wps.com/l/cbCaicqKPqSXfIgo","pdf",6845787,15,"English","# Purpose\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"How were antibodies conjugated with HSP70 used in the study?\",\"answer\":\"Recombinant HSP70 was conjugated with monoclonal antibodies trastuzumab and bevacizumab. The resulting complexes were applied to tumor cells in vitro and in vivo in mouse xenograft models.\"},{\"question\":\"Which tumor cell lines and mechanisms were assessed?\",\"answer\":\"The cytotoxicity of the antibody-HSP70 complex was tested on MCF-7, LS174T, and HEK293T cells. Target expression was characterized, and complement activation pathways were examined using a complement fixation assay.\"},{\"question\":\"What were the key findings regarding immune activation and tumor outcomes?\",\"answer\":\"The complex produced significantly greater cytotoxicity than other treatments on MCF-7 and LS174T cells and activated the classical complement pathway. In xenograft tumors, treatment reduced tumor weight and growth rate, decreased PECAM-1 expression, and showed safety in histopathology.\"}]","The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells | PDF",1790136148,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc3266dc433a85be868c55d385c679ab.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a87c3724dc3adc96a93182e65300d232.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/306874cab8f47550cd8fdac10c02947e.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b2ea155180e8dfb05b8e5ab821f3297.webp",980,1268]